Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMLI, Fludarabine, and Melphalan as Conditioning for Allogeneic PBSC-HCT in Older Patients With Refractory AML and MDS
NCT07582172Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Nov 2026
- Primary completion
- Nov 2031
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by City of Hope. Primary endpoint: Leukemia-Free Survival at 2 years. Started Nov 2026; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT07582172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582172.